{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:45:15Z","timestamp":1767861915986,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Emerg Themes Epidemiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Respiratory syncytial virus (RSV)\u2014the most common viral cause of bronchiolitis\u2014is a significant cause of serious illness among young children between the ages of 0\u20135\u00a0years and is especially concerning in the first year of life. Globally, RSV is a common cause of childhood acute lower respiratory illness (ALRI) and a major cause of hospital admissions in young children and infants and represents a substantial burden for health-care systems. This burden is strongly felt as there are currently no effective preventative options that are available for all infants. However, a renaissance in RSV prevention strategies is unfolding, with several new prophylactic options such as monoclonal antibodies and maternal vaccinations that are soon to be available. A key concern is that health decision makers and systems may not be ready to take full advantage of forthcoming technological innovations. A multi-stakeholder approach is necessary to bridge data gaps to fully utilise upcoming options. Knowledge must be made available at multiple levels to ensure that parents and doctors are aware of preventative options, but also to ensure that stakeholders and policymakers are given the necessary information to best advise implementation strategies.<\/jats:p>","DOI":"10.1186\/s12982-021-00104-5","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T12:02:36Z","timestamp":1634817756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["RSV: perspectives to strengthen the need for protection in all infants"],"prefix":"10.1186","volume":"18","author":[{"given":"Jose Antonio","family":"Navarro Alonso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis J.","family":"Bont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bozzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egbert","family":"Herting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Lega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Mader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta C.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavio","family":"Ramilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Valiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine Weil","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Yates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3410-7642","authenticated-orcid":false,"given":"Saul N.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"issue":"10098","key":"104_CR1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","volume":"390","author":"T Shi","year":"2017","unstructured":"Shi T, McAllister D, O\u2019Brien K, Simoes E, Madhi S, Gessner B, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946\u201358.","journal-title":"Lancet"},{"issue":"5","key":"104_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"MP Griffin","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415\u201325.","journal-title":"N Engl J Med"},{"issue":"4","key":"104_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/14760584.2020.1749597","volume":"19","author":"W Kandeil","year":"2020","unstructured":"Kandeil W, Savic M, Ceregido MA, Guignard A, Kuznetsova A, Mukherjee P. Immune interference (blunting) in the context of maternal immunization with Tdap-containing vaccines: is it a class effect? Expert Rev Vaccines. 2020;19(4):341\u201352.","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"104_CR4","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.vaccine.2019.12.056","volume":"38","author":"JR Jarvis","year":"2020","unstructured":"Jarvis JR, Dorey RB, Warricker FDM, Alwan NA, Jones CE. The effectiveness of influenza vaccination in pregnancy in relation to child health outcomes: systematic review and meta-analysis. Vaccine. 2020;38(7):1601\u201313.","journal-title":"Vaccine"},{"issue":"1","key":"104_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s12916-020-01783-8","volume":"18","author":"PT Campbell","year":"2020","unstructured":"Campbell PT, Geard N, Hogan AB. Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting. BMC Med. 2020;18(1):319.","journal-title":"BMC Med"},{"issue":"41","key":"104_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13052-015-0149-z","volume":"26","author":"M Lanari","year":"2015","unstructured":"Lanari M, Prinelli F, Adorni F, Di Santo S, Vandini S, Silvestri M, et al. Risk factors for bronchiolitis hospitalization during the first year of life in a multicenter Italian birth cohort. Ital J Pediatr. 2015;26(41):40.","journal-title":"Ital J Pediatr"},{"key":"104_CR7","doi-asserted-by":"publisher","first-page":"594898","DOI":"10.3389\/fped.2020.594898","volume":"8","author":"E Bozzola","year":"2020","unstructured":"Bozzola E, Ciarlitto C, Guolo S, Brusco C, Cerone G, Antilici L, et al. Respiratory syncytial virus bronchiolitis in infancy: the acute hospitalization cost. Front Pediatr. 2020;8:594898.","journal-title":"Front Pediatr"},{"issue":"10","key":"104_CR8","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1016\/S2214-109X(17)30344-3","volume":"5","author":"NM Scheltema","year":"2017","unstructured":"Scheltema NM, Gentile A, Lucion F, Nokes DJ, Munywoki PK, Madhi SA, et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet Glob Health. 2017;5(10):e984\u201391.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"104_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10156-002-0178-6","volume":"8","author":"P Pollack","year":"2002","unstructured":"Pollack P, Groothuis J, Barbarotto G. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV. J Infect Chemother. 2002;8(3):201\u20136.","journal-title":"J Infect Chemother"},{"issue":"9859","key":"104_CR10","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095\u2013128.","journal-title":"Lancet"},{"issue":"2","key":"104_CR11","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1542\/peds.2013-0303","volume":"132","author":"C Hall","year":"2013","unstructured":"Hall C, Weinberg G, Blumkin A, Edwards K, Staat M, Schultz A, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341\u20138.","journal-title":"Pediatrics"},{"issue":"5","key":"104_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/jpids\/piz087","volume":"9","author":"CS Arriola","year":"2020","unstructured":"Arriola CS, Kim L, Langley G, Anderson EJ, Openo K, Martin AM, et al. Estimated burden of community-onset respiratory syncytial virus-associated hospitalizations among children aged < 2 years in the United States, 2014\u201315. J Pediatric Infect Dis Soc. 2020;9(5):587\u201395.","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"1","key":"104_CR13","doi-asserted-by":"publisher","first-page":"e20193611","DOI":"10.1542\/peds.2019-3611","volume":"146","author":"B Rha","year":"2020","unstructured":"Rha B, Curns A, Lively J, Campbell A, Englund J, Boom J, et al. Respiratory syncytial virus-associated hospitalizations among young children: 2015\u20132016. Pediatrics. 2020;146(1):e20193611.","journal-title":"Pediatrics"},{"issue":"3","key":"104_CR14","doi-asserted-by":"publisher","first-page":"e0150416","DOI":"10.1371\/journal.pone.0150416","volume":"11","author":"A Pisesky","year":"2016","unstructured":"Pisesky A, Benchimol EI, Wong CA, Hui C, Crowe M, Belair M-A, et al. Incidence of hospitalization for respiratory syncytial virus infection amongst children in Ontario, Canada: a population-based study using validated health administrative data. PLoS ONE. 2016;11(3):e0150416.","journal-title":"PLoS ONE"},{"issue":"5","key":"104_CR15","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/21645515.2019.1688035","volume":"16","author":"A Descamps","year":"2019","unstructured":"Descamps A, Launay O, Bonnet C, Blondel B. Seasonal influenza vaccine uptake and vaccine refusal among pregnant women in France: results from a national survey. Hum Vaccin Immunother. 2019;16(5):1093\u2013100.","journal-title":"Hum Vaccin Immunother"},{"key":"104_CR16","unstructured":"WHO preferred product characteristics for respiratory syncytial virus (RSV) vaccines, initiative for vaccine research (IVR) of the Department of Immunization, Vaccines and Biologicals. 2017. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/258705\/WHO-IVB-17.11-eng.pdf. Accessed 8 Oct 2021."}],"container-title":["Emerging Themes in Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12982-021-00104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12982-021-00104-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12982-021-00104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:32:34Z","timestamp":1736433154000},"score":1,"resource":{"primary":{"URL":"https:\/\/ete-online.biomedcentral.com\/articles\/10.1186\/s12982-021-00104-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["104"],"URL":"https:\/\/doi.org\/10.1186\/s12982-021-00104-5","relation":{},"ISSN":["1742-7622"],"issn-type":[{"value":"1742-7622","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]},"assertion":[{"value":"1 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"An honorarium was paid to SNFs institution for his participation in the expert group but SNF received no personal payments of any kind. SNF has acted as clinical trial investigator on behalf of his hospital for GSK, Janssen (J&J), Regeneron and Medimmune (AstraZeneca) in the field of RSV vaccines and monoclonal antibodies but SNF received no personal payment of any kind. LJB has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. University Medical Centre Utrecht (UMCU) has received major funding (>\u2009\u20ac1,00,000 per industrial partner) for investigator initiated studies from AbbVie, MedImmune, Janssen, the Bill and Melinda Gates Foundation, Nutricia (Danone) and MeMed Diagnostics. UMCU has received major cash or in kind funding as part of the public private partnership Innovative Medicines Initiative-funded Respiratory Syncytial Virus Consortium in Europe project from GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical for participating in the International Network for Optimal Resistance Monitoring of RSV study sponsored by MedImmune. UMCU has received minor funding for participation in trials by Regeneron and Janssen from 2015 to 2017 (total annual estimate\u2009<\u2009\u20ac20,000). UMCU received minor funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, Novavax, Pfizer and Janssen (total annual estimate\u2009<\u2009\u20ac20,000). LJB is the founding chairman of the ReSViNET Foundation. SM reports a sponsorship agreement between SP and EFCNI.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}